272 related articles for article (PubMed ID: 32642869)
21. Analysis of cell cycle regulators: p16INK4A, pRb, and CDK4 in low- and high-grade meningiomas.
Tse JY; Ng HK; Lo KW; Chong EY; Lam PY; Ng EK; Poon WS; Huang DP
Hum Pathol; 1998 Nov; 29(11):1200-7. PubMed ID: 9824096
[TBL] [Abstract][Full Text] [Related]
22. A neurogenic tumor containing a low-grade malignant peripheral nerve sheath tumor (MPNST) component with loss of p16 expression and homozygous deletion of CDKN2A/p16: a case report showing progression from a neurofibroma to a high-grade MPNST.
Tajima S; Koda K
Int J Clin Exp Pathol; 2015; 8(5):5113-20. PubMed ID: 26191206
[TBL] [Abstract][Full Text] [Related]
23. An unusual recurrent high-grade glioneuronal tumor with MAP2K1 mutation and CDKN2A/B homozygous deletion.
Cheaney B; Bowden S; Krause K; Sloan EA; Perry A; Solomon DA; Han SJ; Wood MD
Acta Neuropathol Commun; 2019 Jul; 7(1):110. PubMed ID: 31288852
[No Abstract] [Full Text] [Related]
24. PDGF activation in PGDS-positive arachnoid cells induces meningioma formation in mice promoting tumor progression in combination with Nf2 and Cdkn2ab loss.
Peyre M; Salaud C; Clermont-Taranchon E; Niwa-Kawakita M; Goutagny S; Mawrin C; Giovannini M; Kalamarides M
Oncotarget; 2015 Oct; 6(32):32713-22. PubMed ID: 26418719
[TBL] [Abstract][Full Text] [Related]
25. Clinical significance of CDKN2A homozygous deletion in combination with methylated MGMT status for IDH-wildtype glioblastoma.
Funakoshi Y; Hata N; Takigawa K; Arita H; Kuga D; Hatae R; Sangatsuda Y; Fujioka Y; Sako A; Umehara T; Yoshitake T; Togao O; Hiwatashi A; Yoshimoto K; Iwaki T; Mizoguchi M
Cancer Med; 2021 May; 10(10):3177-3187. PubMed ID: 33838014
[TBL] [Abstract][Full Text] [Related]
26. Differences in global gene expression in melanoma cell lines with and without homozygous deletion of the CDKN2A locus genes.
Bloethner S; Hemminki K; Thirumaran RK; Chen B; Mueller-Berghaus J; Ugurel S; Schadendorf D; Kumar R
Melanoma Res; 2006 Aug; 16(4):297-307. PubMed ID: 16845325
[TBL] [Abstract][Full Text] [Related]
27. Chordoid meningiomas can be sub-stratified into prognostically distinct DNA methylation classes and are enriched for heterozygous deletions of chromosomal arm 2p.
Sievers P; Stichel D; Hielscher T; Schrimpf D; Reinhardt A; Wefers AK; Reuss D; Jones DTW; Bewerunge-Hudler M; Hartmann C; Baumgarten P; Wirsching HG; Winther-Kristensen B; Brokinkel B; Ketter R; Idoate Gastearena MA; Lamszus K; Seiz-Rosenhagen M; Mawrin C; Harter PN; Felsberg J; Hänggi D; Herold-Mende C; Berghoff AS; Weller M; Pfister SM; Wick W; Reifenberger G; Preusser M; von Deimling A; Sahm F
Acta Neuropathol; 2018 Dec; 136(6):975-978. PubMed ID: 30382370
[No Abstract] [Full Text] [Related]
28. Homozygous deletions of CDKN2A caused by alternative mechanisms in various human cancer cell lines.
Raschke S; Balz V; Efferth T; Schulz WA; Florl AR
Genes Chromosomes Cancer; 2005 Jan; 42(1):58-67. PubMed ID: 15495191
[TBL] [Abstract][Full Text] [Related]
29. FISH analysis reveals CDKN2A and IFNA14 co-deletion is heterogeneous and is a prominent feature of glioblastoma.
Al Shboul S; Boyle S; Singh A; Saleh T; Alrjoub M; Abu Al Karsaneh O; Mryyian A; Dawoud R; Gul S; Abu Baker S; Ball K; Hupp T; Brennan PM
Brain Tumor Pathol; 2024 Jan; 41(1):4-17. PubMed ID: 38097874
[TBL] [Abstract][Full Text] [Related]
30. CDKN2A/p16 inactivation in the prognosis of oligodendrogliomas.
Bortolotto S; Chiadò-Piat L; Cavalla P; Bosone I; Chiò A; Mauro A; Schiffer D
Int J Cancer; 2000 Nov; 88(4):554-7. PubMed ID: 11058870
[TBL] [Abstract][Full Text] [Related]
31. Metastatic rhabdoid meningioma with BRAF V600E mutation and good response to personalized therapy: case report and review of the literature.
Mordechai O; Postovsky S; Vlodavsky E; Eran A; Constantini S; Dotan E; Cagnano E; Weyl-Ben-Arush M
Pediatr Hematol Oncol; 2015 Apr; 32(3):207-11. PubMed ID: 25116269
[TBL] [Abstract][Full Text] [Related]
32. CDKN2A gene inactivation in epithelial sporadic ovarian cancer.
Niederacher D; Yan HY; An HX; Bender HG; Beckmann MW
Br J Cancer; 1999 Aug; 80(12):1920-6. PubMed ID: 10471040
[TBL] [Abstract][Full Text] [Related]
33. The prognostic significance of CDKN2A homozygous deletion in IDH-mutant lower-grade glioma and glioblastoma: a systematic review of the contemporary literature.
Lu VM; O'Connor KP; Shah AH; Eichberg DG; Luther EM; Komotar RJ; Ivan ME
J Neurooncol; 2020 Jun; 148(2):221-229. PubMed ID: 32385699
[TBL] [Abstract][Full Text] [Related]
34. The rate of homozygous CDKN2A/p16 deletions in glioma cell lines and in primary tumors.
Hartmann C; Kluwe L; Lücke M; Westphal M
Int J Oncol; 1999 Nov; 15(5):975-82. PubMed ID: 10536182
[TBL] [Abstract][Full Text] [Related]
35. [Homozygous deletion of p16 and p15 genes in laryngeal squamous cell carcinoma].
Li F; Kang N; Li Y; He G; Lin C; Sun X; Gao H; Sun K
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2002 Feb; 19(1):30-2. PubMed ID: 11836682
[TBL] [Abstract][Full Text] [Related]
36. Frequent alterations in p16/CDKN2A identified by immunohistochemistry and FISH in chordoma.
Cottone L; Eden N; Usher I; Lombard P; Ye H; Ligammari L; Lindsay D; Brandner S; Pižem J; Pillay N; Tirabosco R; Amary F; Flanagan AM
J Pathol Clin Res; 2020 Apr; 6(2):113-123. PubMed ID: 31916407
[TBL] [Abstract][Full Text] [Related]
37. Allelic loss at 1p is associated with tumor progression of meningiomas.
Bello MJ; de Campos JM; Kusak ME; Vaquero J; Sarasa JL; Pestaña A; Rey JA
Genes Chromosomes Cancer; 1994 Apr; 9(4):296-8. PubMed ID: 7519053
[TBL] [Abstract][Full Text] [Related]
38. Frequent abnormalities of the p15 and p16 genes in mycosis fungoides and sezary syndrome.
Scarisbrick JJ; Woolford AJ; Calonje E; Photiou A; Ferreira S; Orchard G; Russell-Jones R; Whittaker SJ
J Invest Dermatol; 2002 Mar; 118(3):493-9. PubMed ID: 11874489
[TBL] [Abstract][Full Text] [Related]
39. Tight association of loss of merlin expression with loss of heterozygosity at chromosome 22q in sporadic meningiomas.
Ueki K; Wen-Bin C; Narita Y; Asai A; Kirino T
Cancer Res; 1999 Dec; 59(23):5995-8. PubMed ID: 10606247
[TBL] [Abstract][Full Text] [Related]
40. Comprehensive analysis of CDKN2A status in microdissected urothelial cell carcinoma reveals potential haploinsufficiency, a high frequency of homozygous co-deletion and associations with clinical phenotype.
Chapman EJ; Harnden P; Chambers P; Johnston C; Knowles MA
Clin Cancer Res; 2005 Aug; 11(16):5740-7. PubMed ID: 16115911
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
